Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Brain Neoplasms 293Glioblastoma 263Glioma 208Neuroblastoma 88Neoplasms 62Astrocytoma 57Central Nervous System Neoplasms 54Medulloblastoma 48Breast Neoplasms 44Melanoma 41Sarcoma 40Neurofibromatosis 1 39Meningioma 39Carcinoma, Non-Small-Cell Lung 39Lung Neoplasms 37Ependymoma 37Osteosarcoma 32Rhabdomyosarcoma 31Sarcoma, Ewing 28Neoplasm Metastasis 28Diffuse Intrinsic Pontine Glioma 28Rhabdoid Tumor 27Recurrence 26Oligodendroglioma 24Gliosarcoma 22Wilms Tumor 21Pancreatic Neoplasms 21Pheochromocytoma 20Hepatoblastoma 20Neurofibroma, Plexiform 19

Interventions

atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenoviridae Infections × CNS × 90 days × Clear all
NCT07538128 2026-04-20

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Huashan Hospital

Phase EARLY_PHASE1 Recruiting
10 enrolled
CNS

Adenoviridae Infections, Glioblastoma

NCT06763965 2026-03-23

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1/2 Enrolling by invitation
30 enrolled
CNS

Adenoviridae Infections, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡